Latest developments in metal complexes as anticancer agents
(2022) In Coordination Chemistry Reviews 452.- Abstract
Every year novel biologically active compounds are designed as antitumor agents. This review covers and highlights some of the most important findings described during 2018–2020 to appoint the benefits and drawbacks regarding the activity and toxicity of the metal-based cancer drug candidates. We review new multi-action platinum(IV) prodrugs and other metal complexes with high chemotherapeutic potential, which are designed to overcome cisplatin-resistant cancer cells. We also overview new complexes of Os(II), Ru(II), Ir(III), and Zn(II) used for photodynamic therapy, as well as the complexes conjugated with conventional drugs exhibiting new mechanisms of action. Promising complexes that exceed the selectivity of cisplatin, highly... (More)
Every year novel biologically active compounds are designed as antitumor agents. This review covers and highlights some of the most important findings described during 2018–2020 to appoint the benefits and drawbacks regarding the activity and toxicity of the metal-based cancer drug candidates. We review new multi-action platinum(IV) prodrugs and other metal complexes with high chemotherapeutic potential, which are designed to overcome cisplatin-resistant cancer cells. We also overview new complexes of Os(II), Ru(II), Ir(III), and Zn(II) used for photodynamic therapy, as well as the complexes conjugated with conventional drugs exhibiting new mechanisms of action. Promising complexes that exceed the selectivity of cisplatin, highly effective in vitro and in vivo, against certain types of neoplasms are distinguished in the lung, colon, liver, stomach, breast cancers and others.
(Less)
- author
- Paprocka, Renata ; Wiese-Szadkowska, Małgorzata ; Janciauskiene, Sabina LU ; Kosmalski, Tomasz ; Kulik, Marcelina and Helmin-Basa, Anna
- organization
- publishing date
- 2022
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Antitumor activity, Cisplatin, Cytotoxicity, in vivo, Photodynamic therapy, Prodrug
- in
- Coordination Chemistry Reviews
- volume
- 452
- article number
- 214307
- publisher
- Elsevier
- external identifiers
-
- scopus:85119366566
- ISSN
- 0010-8545
- DOI
- 10.1016/j.ccr.2021.214307
- language
- English
- LU publication?
- yes
- additional info
- Publisher Copyright: © 2021 Elsevier B.V.
- id
- 93d40508-6b99-4405-973d-5807962c271d
- date added to LUP
- 2021-12-02 14:19:48
- date last changed
- 2022-04-27 06:16:46
@article{93d40508-6b99-4405-973d-5807962c271d,
abstract = {{<p>Every year novel biologically active compounds are designed as antitumor agents. This review covers and highlights some of the most important findings described during 2018–2020 to appoint the benefits and drawbacks regarding the activity and toxicity of the metal-based cancer drug candidates. We review new multi-action platinum(IV) prodrugs and other metal complexes with high chemotherapeutic potential, which are designed to overcome cisplatin-resistant cancer cells. We also overview new complexes of Os(II), Ru(II), Ir(III), and Zn(II) used for photodynamic therapy, as well as the complexes conjugated with conventional drugs exhibiting new mechanisms of action. Promising complexes that exceed the selectivity of cisplatin, highly effective in vitro and in vivo, against certain types of neoplasms are distinguished in the lung, colon, liver, stomach, breast cancers and others.</p>}},
author = {{Paprocka, Renata and Wiese-Szadkowska, Małgorzata and Janciauskiene, Sabina and Kosmalski, Tomasz and Kulik, Marcelina and Helmin-Basa, Anna}},
issn = {{0010-8545}},
keywords = {{Antitumor activity; Cisplatin; Cytotoxicity, in vivo; Photodynamic therapy; Prodrug}},
language = {{eng}},
publisher = {{Elsevier}},
series = {{Coordination Chemistry Reviews}},
title = {{Latest developments in metal complexes as anticancer agents}},
url = {{http://dx.doi.org/10.1016/j.ccr.2021.214307}},
doi = {{10.1016/j.ccr.2021.214307}},
volume = {{452}},
year = {{2022}},
}